GlassScriptPhysician profile
Alec S Goldenberg
NPI 1316926330
$3,257.54
in general payments reported to CMS, 2019-2025
45 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.29 · 2022: $279 · 2023: $918 · 2024: $1,221 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.21 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $352.19 | 2023-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $199.73 | 2023-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $178.04 | 2024-2025 | |
| Janssen Biotech, INC. | $175.53 | 2022-2025 | Erleada, Talvey, Darzalex |
| Acrotech Biopharma INC. | $167.64 | 2023-2025 | Beleodaq |
| Genzyme Corporation | $166.58 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $127.31 | 2022-2025 | |
| Abbvie INC. | $126.54 | 2023-2025 | |
| Daiichi Sankyo INC. | $105.12 | 2023-2025 | Injectafer, Enhertu |
| Ipsen Biopharmaceuticals, INC | $104.99 | 2024-2025 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $103.89 | 2023-2025 | Ojjaara, Shingrix |
| Alexion Pharmaceuticals, INC. | $103.77 | 2024-2025 | Ultomiris |
| Octapharma USA, INC. | $96.13 | 2022-2025 | Octagam Immune Globulin (Human) |
| Tempus Ai, INC | $89.09 | 2024-2025 | Xt Cdx |
| Kyowa Kirin, INC. | $79.46 | 2020-2024 | Poteligeo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $76.38 | 2022-2024 | Trodelvy |
| Sobi, INC | $71.98 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.83 | 2023-2024 | Hyqvia |
| Seagen INC. | $63.51 | 2023 | Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $50.95 | 2022-2024 | Opdualag |
| Csl Behring | $49.76 | 2022-2025 | Hizentra |
| Puma Biotechnology, INC. | $49.76 | 2023 | |
| Emd Serono, INC. | $48.89 | 2024-2025 | |
| Incyte Corporation | $48.67 | 2023 | Pemazyre, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $46.97 | 2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $42.60 | 2023-2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $40.05 | 2024-2025 | |
| Amgen INC. | $39.92 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Agios Pharmaceuticals, INC. | $39.31 | 2024 | Pyrukynd |
| Merck Sharp & Dohme LLC | $39.26 | 2023-2024 | Keytruda, Welireg |
| Alnylam Pharmaceuticals INC. | $34.79 | 2024 | Givlaari |
| Mirati Therapeutics, INC. | $29.86 | 2024 | Krazati |
| Taiho Oncology, INC. | $28.17 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $24.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.76 | 2023 | Tagrisso |
| Invivyd INC | $24.45 | 2025 | Pemgarda |
| Genentech USA, INC. | $23.57 | 2025 | Hemlibra |
| Eisai INC. | $21.49 | 2024 | |
| Array Biopharma INC | $21.09 | 2024 | Lorbrena, Braftovi |
| Azurity Pharmaceuticals, INC. | $20.31 | 2024 | Vivimusta |
| Shield Therapeutics INC | $19.68 | 2023 | Accrufer |
| Astellas Pharma US INC | $19.35 | 2024 | Padcev |
| Grifols USA, LLC | $17.18 | 2025 | Gamunex-C |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.